NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

The remaining control arm was a very small percentage of the total trial. A tiny whisp more than 10%. Not useful. Changing it to a measure of just the control arm vs itself doesn’t change the significance of the reason for why they needed the ECA, nor does it improve any conceivable argument for the critics. It’s a ridiculous point of contention. And so many patients crossed over because apparently they were willing to do so, because they wanted DCVax-L. It is likely that patients who did not cross over, did not likely do so by choice but by circumstance, which means that remaining group likely did very badly. So that doesn’t help critics in their argument. It is argumentation simply for argumentation but it doesn’t fortify their arguments most likely, when data comes out.

Shorts seem to think NWBO are hiding some really long-lived patients who recurred but did not crossover. I’d say that is very much not likely.